![Gregory Conn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 108 882 $ au 30/06/2026
Gregory L.
Conn is the founder of PDS Operating Corp.
Dr. Conn is Chief Scientific Officer at PDS Biotechnology Corp.
since 2005.
Dr. Conn was Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn completed graduate and doctorate degrees at Albert Einstein College of Medicine, Inc.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP. 0,22 % | 12/01/2026 | 123 589 ( 0,22 % ) | 108 882 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Directeur Technique/Scientifique/R&D | 01/01/2005 |
| Sociétés | Poste | Fin |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2000 |
PDS Operating Corp.
 PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Fondateur | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. Pharmaceuticals: MajorHealth Technology Develops novel cancer immunotherapies and vaccines for infectious disease | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDS Biotechnology Corp.
 PDS Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Develops clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
